UAE 2nd Country Worldwide To Approve Lung Cancer Drug 'Lumakras'

  • Publish date: Sunday، 20 June 2021
UAE 2nd Country Worldwide To Approve Lung Cancer Drug 'Lumakras'

The UAE's Ministry of Health and Prevention (MoHAP) has recently approved the registration and use of Amgen’s lung cancer drug Lumakras, following the approval of the US Food and Drug Administration (FDA).

This will provide lung cancer patients early access to this innovative drug to help speed up their treatment plan and improve the quality of their life.

LUMAKRAS is supplied as a film-coated tablet for oral use containing 120mg of Sotorasib. The drug is prescribed to adults with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), who have received at least one previous cancer therapy.

The approval of this innovative treatment in the second country in the world comes a week after the UAE approved the emergency use of a highly effective new treatment for COVID-19, becoming the first country in the world to register the drug following the FDA approval.

Dr. Ahmed Mostafa, country manager of Amgen in GCC, said, "We are extremely proud of the UAE's approval for Lumakras drug, making it the second country in the world after the USA that approves and licences the medicine.

Follow us on our Whatsapp channel for latest news